Synthetic biologyBiology as SoftwareAt a recent event researcher and founder of Bit.bio, Prof. Mark Kotter, Babraham Research Campus in Cambridge/UK, was asked what healthcare looks like in 2050. He gave a twofold answer, that it will … more ➔
BiomanufacturingRichter-Helm – how CDMOs become stro...Professionalism and quality are always at the forefront along the whole value chain: from gene to product. To pro-actively meet the evolving demand of the market to produce new assets Richter-Helm significantly … more ➔
BiomanufacturingA novel BPM systemThe biotech and pharma branch is growing steadily. Many companies have full order books for the next few years and expect growth. This is the basis for new investments in assets and infrastructure. These … more ➔
EuropeThe EU Commission strikes again – Ne...In times of the pandemic it was called to ban patents that are related to Covid-19 vaccines, medicaments, and diagnostics and the European Parliament was in favour of it. Now there is a call from the … more ➔
Biotech ClusterPaving the way to internationalisation Due to the global niche character of pharmaceutical biotechnology, research collaborations and market entries on an international level are essential. Agility and market knowledge are required to … more ➔
Drug developmentDerisking drug programs by early lead opti...Antibody engineering?The development of therapeutic antibodies is a time and cost intensive process. Biological and physicochemical properties of the lead molecules influence almost every step in … more ➔
CDMONavigating the CDMO proposal processWhen businesses receive a proposal from a contract development and manufacturing organisation (CDMO), it’s much like a first date: first impressions matter. The proposal process not only reveals a CDMOs … more ➔
Central LaboratoriesChallenges in the central labClinical trials have to be coordinated as a safe process where monitoring, analytics and handling of patient samples is streamlined – even cross oceans. German MLM Medical Labs is quickly establishing … more ➔
BiomanufacturingManufacturing Biopharmaceuticals Within the competitive CDMO market, Richter-Helm has developed into a highly valued partner when it comes to the manufacturing of biopharmaceuticals. Richter-Helm is well recognised by pharmaceutical … more ➔
BerlinInfrastructure makes the difference A well connected and effective infrastructure, a high density of research and development as well as close networking are of great value, not only to founders. Within the successful healthcare cluster … more ➔
